Scott Throner
AstraZeneca (Brazil)(BR)Molecular Oncology (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Neuropeptides and Animal Physiology, Cytokine Signaling Pathways and Interactions, Myeloproliferative Neoplasms: Diagnosis and Treatment, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist(2020)109 cited
- → Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering(2015)62 cited
- → Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor(2020)58 cited
- → Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors(2016)36 cited
- → Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)(2011)33 cited
- → Azepines and Piperidines with Dual Norepinephrine Dopamine Uptake Inhibition and Antidepressant Activity(2012)27 cited
- → Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition(2014)27 cited
- → Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors(2018)26 cited
- → Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1(2010)26 cited
- → SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2(2010)19 cited